Elderly ES-SCLC Patient Outcomes with Immunochemotherapy and Radiotherapy, 1,276 Cases

A retrospective clinical study of 1,276 extensive-stage small cell lung cancer patients, including 350 elderly patients aged 70 or older. The data, authored by Fengxin Sun and last updated in April 2026, analyzes overall and progression-free survival outcomes for first-line immunochemotherapy combined with thoracic radiotherapy. Propensity score matching was applied to a subset of 780 patients to reduce bias.

Use Cases

• Model survival outcomes based on treatment type (immunochemotherapy vs. chemotherapy alone) mentioned in the description
• Assess the interaction effect between thoracic radiotherapy and immunotherapy on patient prognosis
• Analyze treatment safety profiles based on reported hematologic toxicity and adverse event rates
• Investigate prognostic factors for elderly patients with extensive-stage small cell lung cancer

Strengths

• Includes 1,276 patient records with a focused cohort of 350 elderly patients
• Used propensity score matching on 780 patients to address treatment selection bias
• Reports specific hazard ratios and p-values for survival outcomes

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count for the underlying data tables is unknown, which may limit suitability assessment
• Data is from a single-center retrospective study, which may limit generalizability

Provenance

Source

figshare, authored by Fengxin Sun

Collection Method

Single-center retrospective clinical study

Time Range

null

Freshness

Last updated 2026-04-04 13:08:09

Geography

null